ClinicalTrials.gg
CompletedNCT01777334Updated Jan 24, 2018Results posted

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

A Phase 3 interventional study of Umeclidinium/Vilanterol 62.5/25 mcg and Tiotropium 18 mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 70 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
905
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
25th of 236
905 · median 101
Started
2013
with 19 others
Phase 3
65 of 276
5 open now
Registered
166th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 25th largest by enrollment of the 236 interventional ones that give a count, is one of 20 that started in 2013, is one of 65 in phase 3, and was the 166th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects with COPD.

Read the detailed description

This is a Phase IIIb multicenter, randomized, double-dummy, parallel group study to evaluate the efficacy and safety of UMEC/VI Inhalation Powder (62.5/25 mcg) when administered once-daily via a novel dry powder inhaler (DPI) compared with tiotropium (18 mcg) administered once-daily via the HandiHaler over a treatment period of 24 weeks in subjects with COPD. Eligible subjects will be randomized 1:1 to UMEC/VI Inhalation Powder (62.5/25 mcg), or tiotropium (18 mcg) for 24 weeks.

There will be a total of 10 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 7- to 10-day run-in period followed by a 24-week treatment period. Clinic visits will be at Screening, Randomization (Day 1), Day 2 and after 4, 8, 12, 16, 20 and 24 weeks, and 1 day after the Week 24 visit (Visit 1 to Visit 10, respectively). Additionally a safety Follow-Up assessment will be conducted either by phone call or clinic visit where required approximately 7 days after the end of the study treatment (Visit 10 or Early Withdrawal, if applicable). The total duration of subject participation, including the Follow-Up will be approximately 26 weeks.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient.
  • : A signed and dated written informed consent prior to study participation.
  • Age: Subjects 40 years of age or older at Visit 1.
  • Gender: Male or female subjects.

A female is eligible to enter and participate in the study if she is of:

Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy.

OR

Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact):

  • Abstinence
  • Oral Contraceptive, either combined or progestogen alone
  • Injectable progestogen
  • Implants of levonorgestrel
  • Estrogenic vaginal ring
  • Percutaneous contraceptive patches
  • Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label
  • Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records.
  • Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)

    • Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004].
    • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.

Note: Pipe and/or cigar use cannot be used to calculate pack-year history

  • Severity of Disease: A pre and post-albuterol/salbutamol /FVC ratio of \<0.70 and a pre and post-albuterol/salbutamol FEV1 of FEV1 of \<=70% of predicted normal values calculated using NHANES III reference equations at Visit 1 [Hankinson, 1999; Hankinson, 2010].
  • Dyspnea: A score of ≥2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: A current diagnosis of asthma.
  • Other Respiratory Disorders: Known alpha 1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to should be excluded. Examples may include bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • : A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
  • Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
  • 12-Lead : An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, including the presence of a paced rhythm on a 12-lead electrocardiogram (ECG) which causes the underlying rhythm and ECG to be obscured. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. Specific ECG findings that preclude subject eligibility are listed in Appendix 4. The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix 4.
  • Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
  • Use of certain medications according to defined time intervals prior to Screening (Visit 1).
  • Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., >=12 hours per day) is not exclusionary.
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy.
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.
  • Previous use of study drug: Previous participation in DB2113360 or DB2113374.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
905 participants (actual)

Study arms

  • Experimental
    Umeclidinium/Vilanterol

    Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)

    Drug: Umeclidinium/Vilanterol 62.5/25 mcg

  • Active comparator
    Tiotropium

    Long-acting muscarinic antagonist (LAMA)

    Drug: Tiotropium 18 mcg

Interventions

  • DrugUmeclidinium/Vilanterol 62.5/25 mcg

    Inhalation Powder

  • Inhalation Powder

06

What researchers measure

Primary outcomes

  1. Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 140, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes (min) pre-dose and 5 min pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours (hr) after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hr after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 value at that visit minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessmentsmade 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.

    Time frame: Baseline and Day 169

Secondary outcomes

  1. Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as the WM value at that visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.

    Time frame: Baseline and Day 168

07

Results

Posted Jun 5, 2014

Participant flow

Participant flow — Overall Study
MilestoneUMEC/VI 62.5/25 µgTIO 18 µg
Started454451
Completed401388
Not completed5363
Withdrew: Adverse event1814
Withdrew: Lack of efficacy1529
Withdrew: Protocol violation37
Withdrew: Lost to follow-up32
Withdrew: Withdrawal by subject1411

Outcome measures

PrimaryChange From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 140, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes (min) pre-dose and 5 min pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours (hr) after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hr after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 value at that visit minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessmentsmade 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)
LitersUMEC/VI 62.5/25 µgTIO 18 µg
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)0.205 ± 0.01140.093 ± 0.0115
Statistical analysis
  • UMEC/VI 62.5/25 µg vs TIO 18 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.112 · 95% CI 0.081 to 0.144Least squares mean difference=UMEC/VI 62.5/25 µg minus TIO 18 µg.
SecondaryChange From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as the WM value at that visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168
LitersUMEC/VI 62.5/25 µgTIO 18 µg
Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 1680.276 ± 0.01240.170 ± 0.0126

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until the end of treatment (up to 24 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UMEC/VI 62.5/25 µg—16/454 (3.5%)71/454 (15.6%)
TIO 18 µg—17/451 (3.8%)72/451 (16%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventUMEC/VI 62.5/25 µgTIO 18 µg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/4542/451
PneumoniaInfections and infestations0/4542/451
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4541/451
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4541/451
HaemoptysisRespiratory, thoracic and mediastinal disorders0/4541/451
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/4541/451
CholecystitisHepatobiliary disorders1/4541/451
CholelithiasisHepatobiliary disorders0/4541/451
Acute myocardial infarctionCardiac disorders0/4541/451
Angina pectorisCardiac disorders0/4541/451
Most frequent other events
Most frequent other events
EventUMEC/VI 62.5/25 µgTIO 18 µg
HeadacheNervous system disorders40/45431/451
NasopharyngitisInfections and infestations28/45430/451
CoughRespiratory, thoracic and mediastinal disorders13/45415/451

Baseline characteristics

Age, Continuous
Age, Continuous(Years)UMEC/VI 62.5/25 µgTIO 18 µgTotal
Mean61.9 ± 8.4162.7 ± 8.5062.3 ± 8.46
Sex: Female, Male
Sex: Female, Male(Participants)UMEC/VI 62.5/25 µgTIO 18 µgTotal
Female144148292
Male310303613
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UMEC/VI 62.5/25 µgTIO 18 µgTotal
White/Caucasian/European Heritage438442880
African American/African Heritage13720
American Indian or Alaska Native112
White - Arabic/North African Heritage101
Mixed Race112
08

Study locations

70 sites
  • GSK Investigational Site
    Tucson, Arizona 85723, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    San Diego, California 92103-8415, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Panama City, Florida 32405, United States
  • GSK Investigational Site
    Coeur d'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Saint Charles, Missouri 63301, United States
  • GSK Investigational Site
    Omaha, Nebraska 68134, United States
  • GSK Investigational Site
    Columbus, Ohio 43215, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Ciudad Autnónoma de Buenos Aires, Buenos Aires C1186ACB, Argentina
  • GSK Investigational Site
    Dimitrovgrad, 6400, Bulgaria
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4002, Bulgaria
  • GSK Investigational Site
    Ruse, 7000, Bulgaria
  • GSK Investigational Site
    Stara Zagora, 6003, Bulgaria
  • GSK Investigational Site
    Troyan, 5600, Bulgaria
  • GSK Investigational Site
    Varna, 9000, Bulgaria
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4E1, Canada
  • GSK Investigational Site
    Moncton, New Brunswick E1G1A7, Canada
  • GSK Investigational Site
    Burlington, Ontario L7N 3V2, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8L 5G8, Canada
  • GSK Investigational Site
    Toronto, Ontario M3H 5S4, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1N8, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Montreal, Quebec H2R 1V6, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 1Z1, Canada
  • GSK Investigational Site
    St-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    Quebec, G3K 2P8, Canada
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Neu-Isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04103, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04275, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Berlin, 10119, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Hamburg, 20354, Germany
  • GSK Investigational Site
    Balassagyarmat, 2660, Hungary
  • GSK Investigational Site
    Budaörs, 2040, Hungary
  • GSK Investigational Site
    Debrecen, 4032, Hungary
  • GSK Investigational Site
    Gödöllő, 2100, Hungary
  • GSK Investigational Site
    Nyíregyháza, 4400, Hungary
  • GSK Investigational Site
    Szikszó, 3800, Hungary
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucharest, 050159, Romania
  • GSK Investigational Site
    Bucuresti, 70000, Romania
  • GSK Investigational Site
    Cluj Napoca, 400371, Romania
  • GSK Investigational Site
    Codlea, 505100, Romania
  • GSK Investigational Site
    Deva, 330084, Romania
  • GSK Investigational Site
    Barnaul, 656 045, Russian Federation
  • GSK Investigational Site
    Belgorod, 308007, Russian Federation
  • GSK Investigational Site
    Krasnodar, 350012, Russian Federation
  • GSK Investigational Site
    Moscow, 119002, Russian Federation
  • GSK Investigational Site
    Moscow, 123367, Russian Federation
  • GSK Investigational Site
    Pyatigorsk, 357538, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 194354, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 198260, Russian Federation
  • GSK Investigational Site
    Alicante, 03004, Spain
  • GSK Investigational Site
    Mérida (Badajoz), 06800, Spain
  • GSK Investigational Site
    Salt (gerona), 17190, Spain
  • GSK Investigational Site
    Valencia, 46015, Spain
09

References and documents

Publications

  • Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing Short-term Deterioration in Maintenance-naive Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. Adv Ther. 2017 Jan;33(12):2188-2199. doi: 10.1007/s12325-016-0430-6. Epub 2016 Oct 28. PubMed 27796912 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Sep 2013, 8 months.

Results were first posted in Jun 2014, 8 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 8 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2013
First posted
Jan 28, 2013
StartActual
Jan 23, 2013
Primary completionActual
Sep 24, 2013
CompletionActual
Sep 24, 2013
Results first posted
Jun 5, 2014
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01777334
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 28, 2013
Start date
Jan 23, 2013
Primary completion
Sep 24, 2013
Completion
Sep 24, 2013
Results posted
Jun 5, 2014
Last update
Jan 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion